Research progress on prevention and treatment of Alzheimer’s disease with traditional Chinese medicine based on gut microbiota#br#
WANG Yang1 ZHAO Jian2 WANG Di2 YANG Bo3 ZHENG Shijia4 ZHOU Zhongguang1
1.College of Basic Medicine, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China;
2.Department of Acupuncture, the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China; 3.College of Pharmacy, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China;
4.Tianwenshan Agricultural Development Company, Heilongjiang Province, Harbin 150040, China
Abstract:Intestinal microecology is a hotspot of research on life science in recent years. Gut microbiota and its metabolites regulate host’s behavior and cognitive function, and are closely related to the occurrence and development of Alzheimer’s disease (AD), gut microbiota has become a new target for the prevention and treatment of AD. Traditional Chinese medicine has advantages in regulating gut microbiota, and it is widely used in the prevention and treatment of AD. Targeting gut microbiota through traditional Chinese medicine has become a key breakthrough in anti-AD treatment. This paper describes the relationship between gut microbiota and AD, and summarizes the current situation of the research on the control of gut microbiota by traditional Chinese medicine, in order to provide research directions and ideas for strengthening the understanding of AD and the development of anti-AD drugs.
王洋1 赵健2 王迪2 杨波3 郑时嘉4 周忠光1. 基于肠道菌群探讨中药防治阿尔茨海默病的研究进展[J]. 中国医药导报, 2022, 19(3): 38-42.
WANG Yang1 ZHAO Jian2 WANG Di2 YANG Bo3 ZHENG Shijia4 ZHOU Zhongguang1. Research progress on prevention and treatment of Alzheimer’s disease with traditional Chinese medicine based on gut microbiota#br#. 中国医药导报, 2022, 19(3): 38-42.
[1] Lin L,Zheng LJ,Zhang LJ. Neuroinflammation,Gut Microbiome,and Alzheimer’s Disease [J]. Mol Neurobiol,2018,55(11):8243-8250.
[2] Kowalski K,Mulak A. Brain-Gut-Microbiota Axis in Alz-heimer’s Disease [J]. J Neurogastroenterol Motil,2019,25(1):48-60.
[3] Wu XM,Tan RX. Interaction between gut microbiota and ethnomedicine constituents [J]. Nat Prod Rep,2019,36(5):788-809.
[4] Cryan JF,O’Riordan KJ,Cowan CSM,et al. The Microbiota-Gut-Brain Axis [J]. Physiol Rev,2019,99(4):1877-2013.
[5] Long-Smith C,O’Riordan KJ,Clarke G,et al. Microbiota-Gut-Brain Axis:New Therapeutic Opportunities [J]. Annu Rev Pharmacol Toxicol,2020,60:477-502.
[6] Bravo JA,Forsythe P,Chew MV,et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve [J]. Proc Natl Acad Sci U S A,2011,108(38):16050-16055.
[7] Stephenson J,Nutma E,van der Valk P,et al. Inflammation in CNS Neurodegenerative Diseases [J]. Immunology,2018,154(2):204-219.
[8] Daulatzai MA. Role of stress,depression,and aging in cognitive decline and Alzheimer’s disease [J]. Curr Topics Behav Neurosci,2014,18:265-296.
[9] Kesika P,Suganthy N,Sivamaruthi BS,et al. Role of gut-brain axis,gut microbial composition,and probiotic intervention in Alzheimer’s disease [J]. Life Sci,2021,264:118627.
[10] Zhan X,Stamova B,Jin LW,et al. Gram-negative bacterial molecules associate with Alzheimer disease pathology [J]. Neurology,2016,87(22):2324-2332.
[11] 雅迪,李洋洋,刘芳芳,等.减轻脂多糖诱导炎症的中药有效成分的研究进展[J].华西药学杂志,2021,36(3):331-335.
[12] Alam MZ,Alam Q,Kamal MA,et al. A possible link of gut microbiota alteration in type 2 diabetes and Alzheimer’s disease pathogenicity:an update [J]. CNS Neurol Disord Drug Targets,2014,13(3):383-390.
[13] Calvo-Flores Guzmán B,Vinnakota C,Govindpani K,et al. The GABAergic system as a therapeutic target for Alz-heimer’s disease [J]. J Neurochem,2018,146(6):649-669.
[14] Yano JM,Yu K,Donaldson GP,et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis [J]. Cell,2015,161(2):264-276.
[15] Wang T,Hu X,Liang S,et al. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats [J]. Benef Microbes,2015,6(5):707-717.
[16] 张雅欣,路肖,肖碧灵,等.文冠果抗阿尔茨海默症的研究进展及应用前景[J].药物评价研究,2018,41(5):912-917.
[17] Zhou H,Tai J,Xu H,et al. Xanthoceraside Could Ameliorate Alzheimer’s Disease Symptoms of Rats by Affecting the Gut Microbiota Composition and Modulating the Endogenous Metabolite Levels [J]. Front Pharmacol,2019,9(10):1035.
[18] Chen D,Yang X,Yang J,et al. Prebiotic Effect of Fructooligosaccharides from Morinda officinalis on Alzheimer’s Disease in Rodent Models by Targeting the Microbiota-Gut-Brain Axis [J]. Front Aging Neurosci,2017,10(9):403.
[19] Saji N,Niida S,Murotani K,et al. Analysis of the relationship between the gut microbiome and dementia:a cross-sectional study conducted in Japan [J]. Sci Rep,2019,9(1):1008.
[20] Hsiao EY,McBride SW,Hsien S,et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders [J]. Cell,2013, 155(7):1451-1463.
[21] Xie Z,Lu H,Yang S,et al. Salidroside Attenuates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8 Mice and Modulates Inflammation of the Gut-Brain Axis [J]. Front Pharmacol,2020,12(11):568423.
[22] 郭玉倩,陆姜利,角建林,等.人参皂苷Rg1通过调节肠道菌群改善Aβ25-35联合D-半乳糖诱导AD树鼩病理学特征[C]//第十五届中国实验动物科学年会论文集.2019:251-266.
[23] 赵文斌.天麻及其有效物质对阿尔兹海默病模型小鼠的作用机制研究[D].兰州:兰州大学,2019.
[24] 林路宁,姬丽婷,傅云波,等.石菖蒲水提物对3xTg-AD小鼠肠道菌群的影响[J].浙江中医杂志,2020,55(7):471-474.
[25] Wang J,Ye F,Cheng X,et al. The Effects of LW-AFC on Intestinal Microbiome in Senescence-Accelerated Mouse Prone 8 Strain,a Mouse Model of Alzheimer’s Disease [J]. J Alzheimers Dis,2016,53(3):907-919.
[26] Liu Y,Du T,Zhang W,et al. Modified Huang-Lian-Jie-Du Decoction Ameliorates Aβ Synaptotoxicity in a Murine Model of Alzheimer’s Disease [J]. Oxid Med Cell Longev,2019,2019:8340192.
[27] 鲁佳.佛手散调节肠-肝-脑轴改善阿尔茨海默病小鼠认知障碍和海马病理[D].广州:广州中医药大学,2019.
[28] 杨玉芳.当归芍药散对APP/PSN阿尔茨海默病模型小鼠肠道菌群的影响及分子机制[D].芜湖:皖南医学院,2019.
[29] 孙宇飞.基于PK-PD关联分析研究定志小丸治疗阿尔茨海默病的药效物质基础及作用机制[D].合肥:中国科学技术大学,2020.
[30] 徐丹,蔡铮,贾彩,等.2009-2018年国家自然科学基金在防治阿尔茨海默病药物药理学研究领域资助项目分析[J].中国药理学与毒理学杂志,2019,33(5):327-333.